Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
transferrin receptor-directed bispecific
- Development stage
- Preclinical
- Lead developer
- Abzyme Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The transferrin receptor-directed bispecific refers to a preclinical-stage antibody platform developed by Abzyme Therapeutics designed to facilitate the delivery of therapeutic biologics across the blood-brain barrier (BBB). This bispecific antibody format utilizes one binding arm to engage the transferrin receptor (TfR) on brain endothelial cells, triggering receptor-mediated transcytosis to transport the molecule into the central nervous system (CNS). The second binding arm is engineered to target a therapeutic antigen relevant to neurological conditions, such as C1q for complement inhibition or TrkB for neurotrophic signaling. This modular approach aims to overcome the significant challenge of poor BBB permeability for large-molecule drugs, potentially improving treatment outcomes for various CNS disorders.
- Other names
- transferrin receptor-directed bispecific
02
Targets
CD3 (T-cell surface glycoprotein CD3)TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on transferrin receptor-directed bispecific.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on transferrin receptor-directed bispecific.